

Boeing Co/The

The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.


STOCK DESCRIPTION:

Company Name:	Boeing Co/The	Market Capitalization (billion):	112.94
Ticker:	BA US	Estimated EPS:	2.07
Currency:	USD	Estimated P/E:	19.42
ISIN:	US0970231058	Current P/E:	17.64
Last Price:	182.99	Next earnings release date:	2017-04-26
Target Price*:	174.86	Indicated Dividend Yield:	3.10%
Investment Rating*:	Buy	Return on Equity:	136.80%

*Source: Bloomberg consensus

LATEST NEWS:

- Boeing has accepted 1,880 voluntary layoffs from its workers in Seattle as part of the company's attempts to cut costs and optimize operations. The reductions were announced last year and the workers accepted the offers made by the company. All of the cuts have been voluntary and mainly affected workers close to retirement.
- Boeing said it did not have a specific plan with respect to the number of further layoffs and noted that the decision would depend on actual market conditions. The company also mentioned that involuntary job cuts could be applied in some of the cases.
- Shares in Boeing dropped 0.50% on Thursday. US markets were in a slump, absorbing losses in Financials, Materials, and Industrials.



Roche Holding AG

Roche Holding AG develops and manufactures pharmaceutical and diagnostic products. The company produces prescription drugs in the areas of cardiovascular, infectious, autoimmune, respiratory diseases, dermatology, metabolic disorders, oncology, transplantation, and the central nervous system.


STOCK DESCRIPTION:

Company Name:	Roche Holding AG	Market Capitalization (billion):	226.14
Ticker:	ROG VX	Estimated EPS:	15.53
Currency:	CHF	Estimated P/E:	16.88
ISIN:	CH0012032048	Current P/E:	23.32
Last Price:	262.10	Next earnings release date:	2017-07-27
Target Price*:	276.78	Indicated Dividend Yield:	3.13%
Investment Rating*:	Buy	Return on Equity:	42.66%

*Source: Bloomberg consensus

LATEST NEWS:

- A clinical study has shown that Roche's drug Perjeta, used in combination with another cancer drug Herceptin and chemotherapy, proved to be effective in the treatment of an aggressive form of breast cancer. The study indicates that patients treated with the cocktail of Roche's drugs could live longer without a return of the disease.
- The results are widely believed to be a success for Roche, which has been studying the treatment of breast cancer for many years. Analysts, however, emphasized the fact that the company had released only partial results and further tests should be conducted to confirm meaningful improvements in patients' life expectancy.
- Shares in Roche rallied 6.54% on Thursday.



Vodafone Group PLC

Vodafone Group PLC is a mobile telecommunications company providing a range of services, including voice and data communications. The company operates in Continental Europe, the United Kingdom, the United States, Asia Pacific, Africa and the Middle East through its subsidiaries, associates, and investments.


STOCK DESCRIPTION:

Company Name:	Vodafone Group PLC	Market Capitalization (billion):	53.91
Ticker:	VOD LN	Estimated EPS:	0.04
Currency:	GBP	Estimated P/E:	38.07
ISIN:	GB00BH4HKS39	Current P/E:	-
Last Price:	202.50	Next earnings release date:	2017-05-16
Target Price*:	229.92	Indicated Dividend Yield:	5.82%
Investment Rating*:	Buy	Return on Equity:	-10.36%

*Source: Bloomberg consensus

LATEST NEWS:

- Vodafone is launching the world's largest program to recruit women who have taken a break in their careers. The company's ReConnect program will aim at hiring close to 1,000 people over the next three years. Half of the new roles will be created in call centers and shops, while the rest of the incoming hires will fill managerial positions.
- The program will not be restricted to former Vodafone employees and will be directed at helping women adapt to the work environment after having children. The initiative will provide new hires with an opportunity to refresh professional skills and have flexible working hours. If the plan is successful, ReConnect hires will constitute close to 10% of Vodafone's managerial staff.
- Shares in Vodafone closed 0.02% lower on Thursday.



Authors



Andrejs Kočetkovs
Head of the Investment Sales
and Advisory Division



Maksim Naruta
Investment Analyst

CONTACT US

Legal address and details:

Baltikums Bank AS

Office: Maza Pils iela 13,
Rīga, LV-1050, Latvia
info@blueorangebank.com

Investment Sales & Advisory Department:

Phone: +371 67 034 202
investment@blueorangebank.com

www.blueorangebank.com

Important Legal Information

No Offer

Nothing contained herein constitutes an offer, solicitation or recommendation regarding any investment product or service, or the offer to sell or the solicitation of an offer to buy any financial instrument; nor shall any such services be provided, or financial instruments be offered or sold, in any jurisdiction in which such an offer, solicitation, provision or sale would be unlawful. All content is subject to applicable statutes and regulations. Any potential investor should satisfy oneself that an investment in any product and/or service mentioned in this material is permissible under the rules and regulations of his or her domicile. This material is not directed to any person in any jurisdiction where (by reason of that person's nationality, residence or otherwise) the availability of the material is prohibited.

The information provided is for reference only and investors should determine for themselves whether a particular service or product is suitable and appropriate for their investment needs or should seek such professional advice for their particular situation. Please refer to offering documents for further information concerning specific products.

Certain statements contained herein may be statements of future expectations and other forward-looking statements that are based on current views and assumptions of BlueOrange (the trade name operated by the legal entity Baltikums Bank AS – hereinafter referred to as "BlueOrange") and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential, or continue" and similar expressions identify forward-looking statements. BlueOrange assumes no obligation to update any forward-looking information contained herein.

Investments

Past performance is no guarantee of future results. Investing in the financial markets is subject to certain risks including market, interest-rate, issuer, credit, and inflation risk. Financial instruments may appreciate or depreciate in price owing to conditions, whether real or apparent, in a given market, economy or industry. The value of investments, and the income from them, can go down as well as up, and you may not recover the amount of your original investment. Where investments involve currency exposure, changes in rates of exchange may cause the value of the investment to go up or down. Any tax benefits referred to on this material are subject to change and their availability and value will depend on your individual circumstance.

No Reliance

Although BlueOrange has taken reasonable care to ensure that the information contained within this material is accurate, no representation or warranty (including liability towards third parties), expressed or implied, is made as to its accuracy, reliability or completeness by BlueOrange. Opinions and any other contents of the material are provided by BlueOrange for personal use and for tentative reference only. Nothing contained on this material constitutes investment, legal, tax or other advice and is not to be relied on in making an investment or other decision.